Achieving high-quality, efficient mRNA synthesis for streamlined and cost-effective manufacturing

In 2011, Helge Zieler founded Primordial Genetics with the goal of building the premier company for genetic improvement of microbes and enzymes used in bio-production. Today as CEO of Primrose Bio, he is pursuing the same goal with a focus on manufacturing of nucleic acids and proteins used in genetic medicines, vaccines, and biotherapeutics. Helge has been an early participant in multiple biotech companies including Synthetic Genomics and Chromatin. He completed his doctorate in yeast molecular genetics at Stanford University and post-doctoral work in malaria research at the National Institutes of Health.

Khaled Yamout is the founder and and CEO of Yamout Chem Consulting, LLC and he is a thought leader in analytical sciences, quality and manufacturing. He is a member of AMM and serves on multiple committees including the Science and Technology Leadership Committee. Also, he is a volunteer member with USP, where he serves as the chair of the USP Expert Panel on mRNA Vaccines. Previously he held various leadership positions with the most recent position as a Senior Director, Analytical Services and Quality Control at TriLink Biotechnologies where he oversaw the Analytical Sciences Center of Excellence and all analytical aspects of method development and validation to product release and stability to support regulatory filings for both small and large molecules. Prior to TriLink, Yamout held various positions in quality control, R&D, and manufacturing, wherein he supported several drug substances and drug products (both small molecules and biologics) from clinical phase to commercial.